Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults | NIH: National Institute of Allergy and Infectious Diseases

Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults | NIH: National Institute of Allergy and Infectious Diseases

Friday, Jan. 25, 2019 Investigational Monoclonal Antibody to Treat Ebola is Safe in Adults The NIAID-developed investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. The trial took place at the NIH Clinical Center and enrolled 18 healthy adults. The monoclonal antibody is currently being offered to Ebola patients in the Democratic Republic of the Congo under compassionate use and as part of a Phase 2/3 clinical trial.